Takara Shuzo Co., Inc.

Takara Bio Inc.

Taisho Pharmaceutical Co., Ltd.

Hideyo Yamaguchi

Kazutoh Takesako

Ikunoshin Kato

Katsushige Ikai

Teruya Nakamura

Kazuo Shimanaka

Junko Yamamoto

Fumiyo Haruna

Katsuhisa Uchida

Yoshimi Onishi

Kazuo Akiyama

Hiroshi Yasueda

Tomoko Yagihara

Masanobu Kuroda

Takashi Okado

Kiyozo Asada

Hiroyuki Mukai

Sadafumi Omura

Michio Yamagishi

Taku Mizutani

Osamu Takeda

Kazuo Numata

Naoharu Watanabe

Takashi Okada

A substantially pure, isolated, antigenic protein from fungi of the genus, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug forallergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

[object Object]

A substantially pure, isolated, antigenic protein from fungi of the genus, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergies; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug forallergies, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Antigenic protein originating in malassezia

A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

This invention is directed to a gene sequence for secretory aspartic proteinase (SEQ ID No. 1) which is specific to pathogenic Candida yeast, to a highly sensitive method for detection of said gene in a sample solution and a kit used therefor.

Gene encoding aspartic acid secretory proteinase of Candida albicans and

An antibiotic R106 represented by the general formula I): ##STR1## wherein: R is methyl or ethyl;

Aureobasidium pullulans which produces antibiotic R106

There are provided R106 compounds represented by the following general formula (I): ##STR1## wherein: A.sub.1 is Phe, o-FPhe, m-FPhe, or Tyr;

R106 compounds

An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;

Process for the production of antibiotic R106 by a strain of

Novel antibiotics R106

Method for the treatment of systemic mycosis of mammals comprises administering (S)-2-amino-5-hydroxy-4-oxopentanoicacid in a therapeutically effective amount to said mammals suffering from mycosis, typically candidosis.

Method for the treatment of systemic mycosis

Growing community of inventors

Kawasaki, Japan

Hideyo Yamaguchi